Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia.

  • Quantitative Biology Unit
  • Computational Biomedicine
July 08, 2020 By:
  • Aroua N
  • Boet E
  • Ghisi M
  • Nicolau-Travers ML
  • Saland E
  • Gwilliam R
  • de Toni F
  • Hosseini M
  • Mouchel PL
  • Farge T
  • Bosc C
  • Stuani L
  • Sabatier M
  • Mazed F
  • Larrue C
  • Jarrou L
  • Gandarillas S
  • Bardotti M
  • Picard M
  • Syrykh C
  • Laurent C
  • Gotanegre M
  • Bonnefoy N
  • Bellvert F
  • Portais JC
  • Nicot N
  • Azuaje F
  • Kaoma T
  • Joffre C
  • Tamburini J
  • Recher C
  • Vergez F
  • Sarry JE.

Relapses driven by chemoresistant leukemic cell populations are the main cause of mortality for patients with acute myeloid leukemia (AML). Here, we show that the ectonucleotidase CD39 (ENTPD1) is upregulated in cytarabine (AraC)-resistant leukemic cells from both AML cell lines and patient samples in vivo and in vitro. CD39 cell surface expression and activity is increased in AML patients upon chemotherapy compared to diagnosis and enrichment in CD39-expressing blasts is a marker of adverse prognosis in the clinics. High CD39 activity promotes AraC resistance by enhancing mitochondrial activity and biogenesis through activation of a cAMP-mediated adaptive mitochondrial stress response. Finally, genetic and pharmacological inhibition of CD39 eATPase activity blocks the mitochondrial reprogramming triggered by AraC treatment and markedly enhances its cytotoxicity in AML cells in vitro and in vivo. Together, these results reveal CD39 as a new residual disease marker and a promising therapeutic target to improve chemotherapy response in AML.

2020 Jul. Cancer Discov. Online ahead of print.
Other information